Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2026)

InMed Pharmaceuticals has reported Return on Capital Employed over the past 4 years, most recently at 73.0% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 2928.0% year-over-year to 73.0%; the TTM value through Dec 2025 reached 73.0%, up 2928.0%, while the annual FY2025 figure was 66.99%, 757.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 73.0% at InMed Pharmaceuticals, down from 62.19% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 52.02% in Q1 2024 and troughed at 172.51% in Q3 2022.
  • A 4-year average of 92.44% and a median of 75.04% in 2025 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: soared 10517bps in 2023 and later plummeted -6370bps in 2025.
  • Year by year, Return on Capital Employed stood at 118.71% in 2022, then soared by 49bps to 60.98% in 2023, then plummeted by -68bps to 102.27% in 2024, then grew by 29bps to 73.0% in 2025.
  • Business Quant data shows Return on Capital Employed for INM at 73.0% in Q4 2025, 62.19% in Q3 2025, and 75.04% in Q2 2025.